Breaking News, Collaborations & Alliances

Humco, Fagron Enter Merger

For a value of up to $70 million

Humco and Fagron have entered into a merger agreement combining the two companies for a value of up to $70 million. 

 

The merger aims to add value to customers through Fagron’s extensive line of active pharmaceutical ingredients (APIs), product portfolio and strong research and development. While still working under the Humco brand, increased financial flexibility will facilitate continued investment into innovative pharmaceutical products for patients and pharmacies globally as well as into Humco’s state-of-the-art FDA registered, cGMP compliant production facility in Texarkana, TX.

 

“I am pleased to welcome Humco to the Fagron Group. Their high-quality portfolio of branded pharmaceutical products and widely used patented delivery vehicles that are supplied to a broad customer base of pharmacy chains and wholesalers in the U.S., is highly complementary to our extensive range of active pharmaceutical ingredients,” said Rafael Padilla, Fagron’s chief executive officer. “Humco is an excellent strategic fit for Fagron. By combining the two companies we create a strong competitive company with significant scale, strengthening our market position in theU.S. Our global footprint and leading market positions in Europe and South-America will enable us to successfully launch and grow the innovative branded pharmaceutical products and delivery vehicles of Humco outside the U.S. We look forward to welcoming the Humco employees to the Fagron family.”

 

Gregory Pulido, Humco’s chairman and chief executive officer, will transition to the role of executive chairman while Andrew Pulido, Humco’s current president, global pharmaceuticals, will assume the sole role of president at Humco.

 

“We are delighted and proud to become part of the Fagron Group. Being part of a large global organization and a world leader in pharmaceutical compounding, creates a more capable and dynamic company for our customers and employees. We complement each other, selling in adjacent markets with very little customer overlap, enabling a significant number of growth opportunities. said Mr. Pulido

 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters